Moll Matthew, Lutz Sharon M, Ghosh Auyon J, Sakornsakolpat Phuwanat, Hersh Craig P, Beaty Terri H, Dudbridge Frank, Tobin Martin D, Mittleman Murray A, Silverman Edwin K, Hobbs Brian D, Cho Michael H
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
BMJ Open Respir Res. 2020 Nov;7(1). doi: 10.1136/bmjresp-2020-000755.
Family history is a risk factor for chronic obstructive pulmonary disease (COPD). We previously developed a COPD risk score from genome-wide genetic markers (Polygenic Risk Score, PRS). Whether the PRS and family history provide complementary or redundant information for predicting COPD and related outcomes is unknown.
We assessed the predictive capacity of family history and PRS on COPD and COPD-related outcomes in non-Hispanic white (NHW) and African American (AA) subjects from COPDGene and ECLIPSE studies. We also performed interaction and mediation analyses.
In COPDGene, family history and PRS were significantly associated with COPD in a single model (P <0.0001; P<0.0001). Similar trends were seen in ECLIPSE. The area under the receiver operator characteristic curve for a model containing family history and PRS was significantly higher than a model with PRS (p=0.00035) in NHWs and a model with family history (p<0.0001) alone in NHWs and AAs. Both family history and PRS were significantly associated with measures of quantitative emphysema and airway thickness. There was a weakly positive interaction between family history and the PRS under the additive, but not multiplicative scale in NHWs (relative excess risk due to interaction=0.48, p=0.04). Mediation analyses found that a significant proportion of the effect of family history on COPD was mediated through PRS in NHWs (16.5%, 95% CI 9.4% to 24.3%), but not AAs.
Family history and the PRS provide complementary information for predicting COPD and related outcomes. Future studies can address the impact of obtaining both measures in clinical practice.
家族病史是慢性阻塞性肺疾病(COPD)的一个风险因素。我们之前从全基因组遗传标记中开发了一种COPD风险评分(多基因风险评分,PRS)。目前尚不清楚PRS和家族病史在预测COPD及相关结局方面是提供互补信息还是冗余信息。
我们在来自COPDGene和ECLIPSE研究的非西班牙裔白人(NHW)和非裔美国人(AA)受试者中,评估了家族病史和PRS对COPD及COPD相关结局的预测能力。我们还进行了交互作用和中介分析。
在COPDGene研究中,在单一模型中家族病史和PRS均与COPD显著相关(P<0.0001;P<0.0001)。在ECLIPSE研究中也观察到类似趋势。在NHW人群中,包含家族病史和PRS的模型的受试者工作特征曲线下面积显著高于仅包含PRS的模型(p = 0.00035),在NHW人群和AA人群中也显著高于仅包含家族病史的模型(p<0.0001)。家族病史和PRS均与定量肺气肿和气道厚度的测量指标显著相关。在NHW人群中,在相加尺度而非相乘尺度下,家族病史和PRS之间存在弱的正向交互作用(交互作用导致的相对超额风险=0.48,p = 0.04)。中介分析发现,在NHW人群中,家族病史对COPD的影响有很大一部分是通过PRS介导的(16.5%,95%CI为9.4%至24.3%),但在AA人群中并非如此。
家族病史和PRS在预测COPD及相关结局方面提供互补信息。未来的研究可以探讨在临床实践中同时获取这两种测量指标的影响。